Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://lewysiaio978529.wikissl.com/2496822/retatrutide_australia_a_potential_hope_for_obesity_treatment